William Blair Has Optimistic Outlook of TRDA FY2024 Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – William Blair increased their FY2024 EPS estimates for shares of Entrada Therapeutics in a report issued on Tuesday, November 5th. William Blair analyst M. Minter now anticipates that the company will earn $1.19 per share for the year, up from their previous forecast of $0.43. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $0.68 per share. William Blair also issued estimates for Entrada Therapeutics’ Q4 2024 earnings at ($0.69) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.95) EPS.

TRDA has been the topic of a number of other reports. Oppenheimer increased their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday. HC Wainwright increased their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday.

Entrada Therapeutics Stock Performance

Shares of NASDAQ TRDA opened at $19.23 on Thursday. The company’s fifty day moving average price is $16.36 and its 200 day moving average price is $15.63. Entrada Therapeutics has a 1 year low of $10.75 and a 1 year high of $19.85. The company has a market capitalization of $715.36 million, a PE ratio of 6.50 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a net margin of 43.63% and a return on equity of 35.16%. The business had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55.00 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. US Bancorp DE purchased a new position in Entrada Therapeutics in the third quarter worth approximately $42,000. Acadian Asset Management LLC purchased a new position in Entrada Therapeutics in the first quarter worth approximately $79,000. SG Americas Securities LLC purchased a new position in Entrada Therapeutics in the third quarter worth approximately $156,000. Allspring Global Investments Holdings LLC raised its holdings in Entrada Therapeutics by 427.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares in the last quarter. Finally, BayBridge Capital Group LLC acquired a new stake in Entrada Therapeutics during the third quarter worth approximately $464,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Insider Buying and Selling at Entrada Therapeutics

In other news, insider Natarajan Sethuraman sold 2,642 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.09, for a total value of $39,867.78. Following the completion of the sale, the insider now directly owns 183,816 shares in the company, valued at $2,773,783.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, COO Nathan J. Dowden sold 1,904 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.07, for a total transaction of $28,693.28. Following the completion of the sale, the chief operating officer now directly owns 125,996 shares in the company, valued at approximately $1,898,759.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Natarajan Sethuraman sold 2,642 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the transaction, the insider now directly owns 183,816 shares of the company’s stock, valued at approximately $2,773,783.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,187 shares of company stock valued at $155,947 over the last ninety days. Corporate insiders own 7.59% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.